Sodium‐glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta‐analysis
European Journal of Clinical Investigation · 2025-06 · 55 (6)
DOI: 10.1111/eci.14392 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 27.01.2025. Verfasst von Paschalis Karakasis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Transthyretin amyloid cardiomyopathy (ATTR‐CM) commonly leads to heart failure but has traditionally been an exclusion criterion in randomized clinical trials (RCTs) of sodium‐glucose cotransporter 2 inhibitors (SGLT2i); therefore, the effects of these drugs in this population remain undocumented. In light of recent studies, this meta‐analysis aimed to investigate the effect of SGLT2i on the prognosis of patients with ATTR‐CM.
Methods
A comprehensive search of Medline, Scopus, and the Cochrane Library was conducted up to November 17, 2024. Study selection, data extraction and quality assessment were carried out independently by two investigators. Associations of SGLT2i with outcomes were pooled using random‐effects meta‐analyses.
Results
A total of five studies (9766 participants, 4 propensity score‐matched) were included. The use of SGLT2i was associated with significant reductions in all‐cause mortality [hazard ratio (HR) .54, 95% confidence interval (CI) .44–.66], cardiovascular mortality (HR .39, 95% CI .23–.65), major adverse cardiovascular events (HR .71, 95% CI .61–.83), and heart failure hospitalizations (HFHs) (HR .63, 95% CI .52–.77) compared to non‐use. The odds of cardiac arrhythmias were significantly lower among SGLT2i users compared to non‐users [odds ratio (OR) .73, 95% CI .65–.83]. Specifically, SGLT2i use was associated with significant reductions in the odds of atrial fibrillation (AF) (OR .75, 95% CI .62–.91), ventricular tachycardia (OR .72, 95% CI .59–.88), and sudden cardiac arrest (OR .71, 95% CI .50–.99).
Conclusions
The use of SGLT2is may be associated with a more favourable prognosis in patients with ATTR‐CM. Adequately powered, long‐term RCTs are required to validate the available observational evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Second Propedeutic Department of Internal Medicine, Faculty of Medicine, School of Health Sciences Aristotle, University of Thessaloniki, Thessaloniki, Greece.
- Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Faculty of Medicine, KU Leuven, Leuven, Belgium.
- Primary Health Care Center, Faculty of Medicine, University of Montenegro, Podgorica, Montenegro.
ORCID-Profile: Paschalis Karakasis, Panagiotis Theofilis, Dimitrios Patoulias, Art Schuermans, Aleksandra Klisic, Manfredi Rizzo, Nikolaos Fragakis
Zitieren
APA
Karakasis, P., Theofilis, P., Patoulias, D., Schuermans, A., Vlachakis, P. K., Klisic, A., Rizzo, M., & Fragakis, N. (2025). Sodium‐glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta‐analysis. European Journal of Clinical Investigation, 55(6). https://doi.org/10.1111/eci.14392
Vancouver
Karakasis P, Theofilis P, Patoulias D, Schuermans A, Vlachakis PK, Klisic A, et al. Sodium‐glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta‐analysis. European Journal of Clinical Investigation. 2025;55(6). doi:10.1111/eci.14392
BibTeX
@article{Karakasis2025,
author = {Karakasis, Paschalis and Theofilis, Panagiotis and Patoulias, Dimitrios and Schuermans, Art and Vlachakis, Panayotis K and Klisic, Aleksandra and Rizzo, Manfredi and Fragakis, Nikolaos},
title = {Sodium‐glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta‐analysis},
journal = {European Journal of Clinical Investigation},
year = {2025},
volume = {55},
number = {6},
doi = {10.1111/eci.14392}
}
EUVIMED